Molecular staging of colorectal cancer
Autor: | Susan R. Stapleton, David S. Reinhold, Jennifer S. Thebo, Anthony J. Senagore |
---|---|
Rok vydání: | 2000 |
Předmět: |
Adult
Male Oncology medicine.medical_specialty Pathology Colorectal cancer DNA Mutational Analysis Adenocarcinoma Polymerase Chain Reaction Metastasis Internal medicine medicine Carcinoma Adjuvant therapy Humans Point Mutation Lymph node Alleles Aged DNA Primers Neoplasm Staging Retrospective Studies Aged 80 and over business.industry Micrometastasis Gastroenterology DNA Neoplasm General Medicine Middle Aged medicine.disease Survival Rate Genes ras medicine.anatomical_structure Lymphatic Metastasis Female Lymph Nodes Lymph Neoplasm Recurrence Local Colorectal Neoplasms business |
Zdroj: | Diseases of the Colon & Rectum. 43:155-159 |
ISSN: | 0012-3706 |
DOI: | 10.1007/bf02236973 |
Popis: | PURPOSE. Multiple attempts have been made to improve the clinical/pathologic staging system of Dukes to focus adjuvant therapy decisions. The purpose of this study was to determine whetherK-ras mutational status of regional nodes in patients with Dukes B2 colorectal cancer could be used to stage their disease more accurately. METHODS: Using formalin-fixed, paraffin-embedded archival material, tumor samples were screened forK-ras mutations using a mutation-specific polymerase chain reaction method, followed by gel electrophoresis in a 96-well array. Patients with Dukes B2 tumors that have mutations in codon 12 or 13 of theK-ras gene were identified. RESULTS: Mutational analysis of the lymph nodes from these patients revealed an 80 percent (16/20) incidence of the same mutations in regional lymph nodes. None of the four patients with mutation-free nodes developed recurrence compared with 37.5 percent (6/16) withK-ras positive lymph nodes. CONCLUSIONS: The data suggest that patients with Dukes B2 colorectal cancers that have mutations in codon 12 or 13 of theK-ras gene are at high risk for the development of nodal metastases. Mutational analysis of the lymph nodes identifies high-risk patients who should be considered for adjuvant chemotherapy. Therefore,K-ras mutational analysis should be considered for molecular staging of colorectal cancer. |
Databáze: | OpenAIRE |
Externí odkaz: |